Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2018

  • ID: 4662588
  • Drug Pipelines
  • 52 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc
  • MedImmune LLC
  • MimeTech Srl
  • Pfizer Inc
  • Serometrix LLC
  • MORE
Beta Nerve Growth Factor (Beta NGF or NGF) - Pipeline Review, H2 2018

Summary

Beta Nerve Growth Factor (Beta NGF or NGF) - Nerve growth factor is a neurotrophic factor involved in the regulation of growth, maintenance, proliferation, and survival of certain target neurons. It inhibits metalloproteinase dependent proteolysis of platelet glycoprotein VI.

Beta Nerve Growth Factor (Beta NGF or NGF) pipeline Target constitutes close to 10 molecules. Out of which approximately 10 molecules are developed by Companies.The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 2, 4 and 1 respectively. Report covers products from therapy areas Central Nervous System, Cardiovascular, Ophthalmology, Dermatology, Hematological Disorders, Immunology and Metabolic Disorders which include indications Osteoarthritis Pain, Cancer Pain, Low Back Pain, Pain, Amyotrophic Lateral Sclerosis, Cardiac Arrest, Diabetic Neuropathy, Glaucoma, Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), Keratitis, Lung Transplant Rejection, Myocardial Infarction, Optic Nerve Injury, Parkinson's Disease, Peripheral Nerve Injury, Post-Operative Pain, Pressure Ulcers, Retinitis Pigmentosa (Retinitis), Sicca Syndrome (Sjogren) and Sickle Cell Disease.

The latest report Beta Nerve Growth Factor - Pipeline Review, H2 2018, outlays comprehensive information on the Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Beta Nerve Growth Factor (Beta NGF or NGF)
  • The report reviews Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Beta Nerve Growth Factor (Beta NGF or NGF) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Beta Nerve Growth Factor (Beta NGF or NGF)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Beta Nerve Growth Factor (Beta NGF or NGF) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Astellas Pharma Inc
  • MedImmune LLC
  • MimeTech Srl
  • Pfizer Inc
  • Serometrix LLC
  • MORE
Introduction

Report Coverage

Beta Nerve Growth Factor (Beta NGF or NGF) - Overview

Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Beta Nerve Growth Factor (Beta NGF or NGF) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Beta Nerve Growth Factor (Beta NGF or NGF) - Companies Involved in Therapeutics Development

Astellas Pharma Inc

Fujimoto Pharmaceutical Corp

MedImmune LLC

MimeTech Srl

Pfizer Inc

Regeneron Pharmaceuticals Inc

Serometrix LLC

Beta Nerve Growth Factor (Beta NGF or NGF) - Drug Profiles

ASP-6294 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fasinumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate NGF for Diabetic Neuropathy and Peripheral Nerve Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-7352 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MT-8 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RBM-004 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Activate NGF Beta for Optic Nerve Injury - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NGF for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tanezumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Beta Nerve Growth Factor (Beta NGF or NGF) - Dormant Products

Beta Nerve Growth Factor (Beta NGF or NGF) - Discontinued Products

Beta Nerve Growth Factor (Beta NGF or NGF) - Product Development Milestones

Featured News & Press Releases

Aug 17, 2018: Fasinumab Phase III osteoarthritis trial meets endpoints

Jul 20, 2018: Pfizer and Eli Lilly report positive results from Phase III tanezumab

Aug 17, 2017: Notice of the Start of a Japanese Phase 2/3 Clinical Study of the Anti-NGF Antibody MT-5547 in Osteoarthritis

Jun 13, 2017: Pfizer and Lilly Receive FDA Fast Track Designation for Tanezumab

Oct 17, 2016: Regeneron and Teva Provide Update on Fasinumab Clinical Development Programs

May 02, 2016: Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain

Mar 23, 2015: Pfizer And Lilly Preparing To Resume Phase 3 Chronic Pain Program For Tanezumab

Mar 12, 2012: FDA Panel Recommends Development Of NGF Inhibitors

Dec 27, 2010: FDA Halts Development Of Regeneron’s Pain Drug

Jul 19, 2010: Pfizer Suspends Chronic Pain Studies In Tanezumab Clinical Trial Program

Jun 23, 2010: Pfizer Suspends Osteoarthritis Clinical Program For Tanezumab

May 12, 2010: Regeneron Provides Initial Data On REGN

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Astellas Pharma Inc, H2 2018

Pipeline by Fujimoto Pharmaceutical Corp, H2 2018

Pipeline by MedImmune LLC, H2 2018

Pipeline by MimeTech Srl, H2 2018

Pipeline by Pfizer Inc, H2 2018

Pipeline by Regeneron Pharmaceuticals Inc, H2 2018

Pipeline by Serometrix LLC, H2 2018

Dormant Products, H2 2018

Dormant Products, H2 2018 (Contd..1), H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Astellas Pharma Inc
  • Fujimoto Pharmaceutical Corp
  • MedImmune LLC
  • MimeTech Srl
  • Pfizer Inc
  • Regeneron Pharmaceuticals Inc
  • Serometrix LLC
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll